Literature DB >> 7513252

Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications.

J F Ross1, P K Chaudhuri, M Ratnam.   

Abstract

BACKGROUND: Despite significant differences in ligand binding between the two known isoforms of the human membrane folate receptor (FR), designated herein as FR-beta (placenta) and FR-alpha (placenta, KB cells), little is known about their tissue specificities, and there is no report on the relative expression of FR-beta in any tissue other than in placenta.
METHODS: The mRNA for each FR isoform in a wide variety of normal fetal and adult tissue explants, primary normal cell cultures, malignant tumor explants, and established tumor cell lines was estimated by a polymerase chain reaction assay. Total receptor levels were estimated by a [3H] folic acid binding assay.
RESULTS: Both the FR isoforms were expressed in fetal as well as adult tissues. Normal tissues generally expressed low to moderate amounts of FR-beta. FR-alpha alone was expressed in normal epithelial cells and was frequently strikingly elevated in a variety of carcinomas, with the exception of squamous cell carcinomas of the head and neck. In contrast, a variety of malignant tissues of nonepithelial origin generally expressed elevated levels of FR-beta alone. Established tumor cell lines expressed FR-alpha virtually alone and did not reflect FR expression patterns in vivo. KB cells and JEG-3 cells grown at low folate concentrations further up-regulated FR-alpha but not FR-beta.
CONCLUSIONS: Although FR-beta is the more common isoform, FR-alpha and FR-beta are differentially regulated in normal tissues, carcinomas, nonepithelial malignancies, and immortalized cells or in response to changes in extracellular folate concentrations. The tissue specificity of FR isoforms and their elevation in malignant tissues may be a significant factor in FR-mediated folate uptake, in tissue responsiveness to promising novel antifolates, and in FR-related immunodiagnosis/immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513252     DOI: 10.1002/1097-0142(19940501)73:9<2432::aid-cncr2820730929>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  165 in total

1.  Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor.

Authors:  Antonio Quintana; Ewa Raczka; Lars Piehler; Inhan Lee; Andrzej Myc; Istvan Majoros; Anil K Patri; Thommey Thomas; James Mulé; James R Baker
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

2.  Synthesis of folate-functionalized RAFT polymers for targeted siRNA delivery.

Authors:  Danielle S W Benoit; Selvi Srinivasan; Andrew D Shubin; Patrick S Stayton
Journal:  Biomacromolecules       Date:  2011-06-10       Impact factor: 6.988

Review 3.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

4.  Folate-immunoglobulin G as an anticancer therapeutic antibody.

Authors:  Hong Li; Yanhui Lu; Longzhu Piao; Jun Wu; Xiaojuan Yang; Sri Vidya Kondadasula; William E Carson; Robert J Lee
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

5.  Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model.

Authors:  Meredith K Chuk; Diane E Cole; Cynthia McCully; Natalia A Loktionova; Anthony E Pegg; Robert J Parker; Gary Pauly; Brigitte C Widemann; Frank M Balis; Elizabeth Fox
Journal:  Cancer Chemother Pharmacol       Date:  2010-08-20       Impact factor: 3.333

6.  Quantification of endocytosis using a folate functionalized silica hollow nanoshell platform.

Authors:  Sergio Sandoval; Natalie Mendez; Jesus G Alfaro; Jian Yang; Sharraya Aschemeyer; Alex Liberman; William C Trogler; Andrew C Kummel
Journal:  J Biomed Opt       Date:  2015-08       Impact factor: 3.170

7.  Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival.

Authors:  Maryelise Cieslewicz; Jingjing Tang; Jonathan L Yu; Hua Cao; Maja Zavaljevski; Koka Motoyama; Andre Lieber; Elaine W Raines; Suzie H Pun
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-17       Impact factor: 11.205

8.  A complementary strategy for enhancement of nanoparticle intracellular uptake.

Authors:  Yingjia Li; Ge Wen; Dongxiao Wang; Xia Zhang; Yaoyong Lu; Jianguo Wang; Lijuan Zhong; Hongbing Cai; Xingmei Zhang; Ying Wang
Journal:  Pharm Res       Date:  2014-02-21       Impact factor: 4.200

9.  Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands.

Authors:  Wei He; Sumith A Kularatne; Kimberly R Kalli; Franklyn G Prendergast; Robert J Amato; George G Klee; Lynn C Hartmann; Philip S Low
Journal:  Int J Cancer       Date:  2008-10-15       Impact factor: 7.396

10.  Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device.

Authors:  Shanta Dhar; Zhuang Liu; Jürgen Thomale; Hongjie Dai; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2008-07-29       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.